

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Rifen 100 mg/ml solution for injection for horses, cattle and pigs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

**Active substance:**

Ketoprofen 100 mg

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Benzyl alcohol (E1519)	10 mg
Arginine	
Citric acid monohydrate (for pH adjustment)	
Water for injection	

Clear, colourless to brownish-yellowish solution for injection.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Horses, cattle, pigs

#### **3.2 Indications for use for each target species**

**Horses**

Diseases affecting the osteoarticular and muscular-skeletal system associated with acute pain and inflammation:

- Lameness of traumatic origin
- Arthritis
- Osteitis, spavin
- Tendinitis, bursitis
- Naviculitis
- Laminitis
- Myositis

Ketoprofen is also indicated for post-surgical inflammation, symptomatic therapy of colic and fever.

### **Cattle**

Diseases associated with inflammation, pain or fever:

- Respiratory diseases
- Mastitis
- Osteoarticular and muscular-skeletal disorders such as lameness, arthritis and to ease uprise post parturition
- Injuries

For the relief of post-operative pain associated with dehorning in calves.

### **Pigs**

Diseases associated with inflammation, pain or fever:

- Treatment associated with the Postpartum Dysgalactia Syndrome/Mastitis Metritis Agalactia (MMA) Syndrome
- Respiratory tract infections
- Symptomatic treatment of fever

For the short-term relief of post-operative pain associated with minor soft tissue surgery such as castration in piglets.

Where necessary ketoprofen should be combined with appropriate antimicrobial therapy.

## **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance, or to any of the excipients.

Do not use in animals suffering from gastrointestinal lesions, haemorrhagic diathesis, impaired hepatic, renal or cardiac function.

Do not use with other NSAID drugs concurrently or within 24 hours of each other.

## **3.4 Special warnings**

Treatment of piglets with ketoprofen before castration reduces post-operative pain for 1 hour. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

Treatment of calves with ketoprofen before dehorning reduces post-operative pain. Ketoprofen alone will not provide adequate pain relief during the dehorning procedure. To obtain pain relief during dehorning co-medication with an appropriate local anaesthetic is needed.

## **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Avoid intra-arterial injection. Do not exceed recommended dose or period of treatment. Special care should be taken when administering the veterinary medicinal product to animals with severe dehydration, hypovolaemia and hypotension as there is a potential risk of increased renal toxicity.

The use of ketoprofen is not recommended in foals under the age of 15 days. Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful management. See section 3.7 regarding the use of the veterinary medicinal product in pregnant mares and sows.

Sufficient drinking water must be supplied at all times during treatment.  
In colic, a subsequent dose may be given only after a thorough re-examination.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. People with known hypersensitivity to ketoprofen or benzyl alcohol should avoid contact with the veterinary medicinal product.

Avoid splashes on the skin and eyes. Rinse thoroughly with water should this occur. If irritation persists seek medical advice. Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

#### Horses, cattle, pigs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction, Anaphylaxis <sup>1</sup> .
Undetermined frequency (cannot be estimated from the available data):	Gastrointestinal irritation <sup>2</sup> , Gastric ulceration <sup>2</sup> , Small intestine ulcer <sup>2</sup> ; Renal disorder <sup>2</sup> ; Injection site irritation <sup>3</sup> ; Inappetence <sup>4</sup> .

<sup>1</sup> Anaphylaxis may be life-threatening and should be treated symptomatically.

<sup>2</sup> Due to the mechanism of action of NSAIDs (inhibition of prostaglandin synthesis).

<sup>3</sup> Transient, caused by intramuscular injections.

<sup>4</sup> Only in pigs, due to repeated administration, reversible.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy:

The safety of ketoprofen has been investigated in pregnant laboratory animals and cattle and no adverse effects were noted. The veterinary medicinal product can be used in pregnant cows.

In absence of studies on pigs use only according to the benefit-risk assessment by the responsible veterinarian. Do not use in pregnant mares.

#### Lactation:

Can be used in lactating cows.

### **3.8 Interaction with other medicinal products and other forms of interaction**

The veterinary medicinal product must not be administered in conjunction with, or within 24 hours of administration of other NSAIDs and glucocorticoids. Concurrent administration of diuretics, nephrotoxic drugs and anticoagulative drugs should be avoided.

Ketoprofen is highly bound to plasma proteins, and may displace or be displaced by other highly protein bound medicines, such as anticoagulants with the possibility of consequent toxic effects due to the unbound fraction of the drug. Due to the fact that ketoprofen may inhibit platelet aggregation and cause gastrointestinal ulceration, it should not be used with other medicines that have the same profile of adverse drug reactions.

### **3.9 Administration routes and dosage**

Horses: Intravenous use (i.v.)

Cattle: Intravenous or intramuscular use (i.v. or i.m.)

Pigs: Intramuscular use (i.m.)

To ensure a correct dosage, body weight should be determined as accurately as possible.

#### **Horses:**

2.2 mg ketoprofen/kg body weight/day intravenously once daily for up to 3 to 5 consecutive days, i.e. 1 ml per 45 kg body weight.

In order to treat colic one injection is normally sufficient. A second administration of ketoprofen requires a reassessment of the patient's clinical status. See section 3.5 Special precautions for use.

#### **Cattle:**

3 mg ketoprofen/kg body weight/day intravenously or deep intramuscularly once daily for up to 3 consecutive days, i.e. 3 ml per 100 kg body weight.

For the relief of post-operative pain associated with dehorning the veterinary medicinal product should be administered as a single injection intravenously or deep intramuscularly 10 – 30 minutes before the procedure.

In cattle, the volume per injection site for i.m. injection should not exceed 9 ml. If the injection volume exceeds 9 ml, this volume should be divided into multiple doses, administered at different injection sites.

**Pigs:**

3 mg ketoprofen/kg body weight as a single deep intramuscular injection, i.e. 3 ml per 100 kg body weight (= 0.03 ml/kg).

For reduction of post-operative pain the veterinary medicinal product should be injected 10 - 30 minutes before surgical intervention. Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device (i.e.: low dose syringe).

**3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Overdose with NSAIDs can lead to gastrointestinal ulceration, loss of proteins, hepatic and renal impairment. In tolerance studies performed in pigs up to 25 % of the animals treated at three times the maximum recommended dose (9 mg/kg) for three days or at the recommended dose (3 mg/kg) for triple the maximum recommended time (9 days) showed erosive and/or ulcerative lesions in both the aglandular (pars oesophagica) and glandular parts of the stomach. Early signs of toxicity include loss of appetite and pasty faeces or diarrhoea. If overdose symptoms are observed, symptomatic treatment should be initiated. The occurrence of ulcers is dose dependent to a limited extent.

**3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

*(to be completed in accordance with national requirements)*

**3.12 Withdrawal periods**

Meat and offal:

Horses: 1 day (24 hours)

Cattle: i.v. 1 day (24 hours)

i.m. 3 days (72 hours)

Pigs: 4 days

Milk (cattle): Zero hours

Not authorised for use in mares producing milk for human consumption.

**4. PHARMACOLOGICAL INFORMATION**

**4.1 ATCvet code: QM01AE03**

**4.2 Pharmacodynamics**

Ketoprofen is a non-steroidal anti-inflammatory drug. In addition to the anti-inflammatory effect, it also exerts an anti-pyretic and analgesic effect. The

pharmacological mechanism of action of ketoprofen is based on the inhibition of the cyclo-oxygenase and lipoxygenase. Ketoprofen also prevents the formation of bradykinin and stabilises the cell membranes of lysosomes, which inhibits the release of lysosomal enzymes that mediate tissue destruction.

### **4.3 Pharmacokinetics**

Ketoprofen is rapidly absorbed after intramuscular administration. Maximum plasma concentration is reached within 30 to 60 minutes. Absolute bioavailability after intramuscular administration in cattle and pigs is 90 - 100%, in the horse 70%. The volume of distribution and clearance are approximately 0.17 L/kg and 0.3 L/kg respectively. Linear kinetics prevails.

The plasma half-life after intramuscular administration is 2 to 3 hours. Ketoprofen binds 95% to plasma proteins and is metabolised by reduction to the secondary alcohol. It is excreted rapidly, mainly via the urine i.e. 80% of the dose administered are eliminated within 12 hours. The reduced ketoprofen metabolite prevails in cattle, the glucuronidated conjugate in horses.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years  
Shelf life after first opening the immediate packaging: 28 days

### **5.3 Special precautions for storage**

Keep the glass vial in the outer carton in order to protect from light.  
After first opening the immediate packaging do not store above 25 °C.

### **5.4 Nature and composition of immediate packaging**

50 ml, 100 ml, 10 x 50 ml, 10 x 100 ml  
Amber glass vials type II, with bromobutyl rubber stopper type I and aluminium caps.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.  
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with

any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

VetViva Richter GmbH

**7. MARKETING AUTHORISATION NUMBER**

Vm 57446/3000

**8. DATE OF FIRST AUTHORISATION**

12 March 2010

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

August 2024

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

*Gavin Hall*  
Approved: 21 January 2025